

DMD #49312

Species Differences in Biliary Clearance and Possible Relevance of Hepatic Uptake and Efflux Transporters Involvement

Ken Grime and Stuart W. Paine

Respiratory & Inflammation DMPK, AstraZeneca R&D, Mölndal, Sweden (KG)

School of Veterinary Medicine and Science, University of Nottingham, College Road,
Sutton Bonington, Leicestershire, LE12 5RD, UK (SWP)

DMD #49312

Running title: Species differences in biliary excretion

Corresponding author:

Ken Grime

Respiratory & Inflammation DMPK, AstraZeneca R&D, Mölndal, SE 43183 Mölndal

Sweden, Tel: +46 (0)317761815, FAX: +46 (0)317762800

ken.grime@astrazeneca.com

Number of text pages: 37

Number of tables: 4

Number of figures: 2

Number of references: 95

Number of words in abstract: 173

Number of words in introduction: 741

Number of words in discussion: 1139

Abbreviations:

BCRP: breast cancer resistance protein

C_{p,ss}: plasma concentration of drug at steady state

C_{p,mid}: plasma concentration of drug at the mid-point of the bile collection interval

MRP2: multidrug resistance-associated protein 2

OAT: organic anion transporter

OATP: organic anion transporting polypeptide

OCT: organic cation transporter

P-gp: P-glycoprotein

DMD #49312

Abstract

From a search of the available literature, a database of twenty two drugs of all charge types and several different therapeutic classes was compiled in order to compare rat and human biliary clearance data. Dog biliary excretion data was also found for nine of the drugs. For nineteen of the twenty two drugs (86%), rat unbound biliary clearance values, when normalized for body weight, exceeded those for man by factors ranging from 9 to over 2500-fold, whereas human/dog differences were much less dramatic. It was possible to define hepatic uptake and efflux transporter involvement for many of the drugs. Based on the findings it is postulated that regardless of the biliary efflux transporters implicated, when drugs do not require active hepatic uptake to access the liver there may be fairly insignificant differences in rat, dog and human biliary clearance. Conversely, when the organic anion-transporting polypeptide drug transporters are involved, one may expect at least a ten-fold discrepancy in rat to human biliary clearance normalized for body weight and corrected for plasma protein binding.

DMD #49312

Introduction

Predicting human pharmacokinetics from pre-clinical data is a primary goal of Drug Discovery DMPK scientists, since therapeutic success can be compromised by poor human PK. Accurate predictions of hepatic metabolic clearance can be made from *in vitro* data providing appropriate attention to detail is made (Sohlenius-Sternbeck et al., 2012; Obach, 2011; Grime & Riley, 2006), but besides being eliminated from the body by metabolism, drugs can be eliminated directly into the urine or bile. Both routes are complex and involve passive and active cellular uptake and efflux transport processes. Biliary excretion can involve the hepatic uptake transporters organic anion transporting polypeptide (OATP), organic anion transporter (OAT) and organic cation transporter (OCT) and the canalicular efflux transporters breast cancer resistance protein (BCRP), P-glycoprotein (P-gp) and multidrug resistance-associated protein 2 (MRP2) (Kusuhara et al. and Sugiyama, 2010; Shitara et al., 2006). Similarly, active renal excretion of drugs can involve several transporters in the basolateral and apical membranes (Brown et al., 2008). Despite the complexity, an effective prediction method based on dog renal clearance after correction for differences in plasma protein binding and kidney blood flow has emerged (Paine et al., 2010). There has not been a wealth of literature on the subject of predicting human biliary clearance of drug candidates, perhaps because of the scarcity of relevant clinical data (Lavé et al., 2009) and as such, in terms of human clearance predictions, biliary stands apart as a largely unresolved problem.

Sandwich-cultured hepatocytes maintain liver-specific functions for several days after cell isolation and exhibit the formation of bile canaliculi and the localization of efflux transporters on the canalicular membrane (LeCluyse et al., 1994).

DMD #49312

Advancements have been made in using this *in vitro* technique for predicting biliary clearance (Abe et al., 2008) but the robustness of the method is still to be extensively tested with a wide range of drugs. However, appreciation of the intracellular drug concentrations and calculation of an *in vitro* biliary intrinsic clearance may see the method emerge as a truly predictive tool (Nakakariya et al., 2012). Nonetheless, pre-clinical *in vivo* data retains an extremely important role in facilitating the understanding and contextualization of the risks associated with human pharmacokinetic predictions. A variety of inter-species allometric scaling approaches have been assessed specifically for biliary clearance (Mahmood 2005; Mahmood and Sahajwalla 2002; Sawada et al., 1984) but given the low number of drugs used in the analyses, the fact that some of the examples used involved total drug related material excreted rather than parent drug (Scatina et al., 1989) and that allometry under-predicts human biliary clearance for some drugs but not others (Påhlman et al., 1998; Sawada et al., 1984), a more extensive analysis has been required.

Recently a database of eighteen drugs having known rat and human biliary clearance was published, representing the most extensive dataset to date (Morris et al., 2012). From this it was evident that, when considering unbound clearance (corrected for plasma protein binding), simple allometry using an exponent of 0.66 gave reasonable human predictions for some drugs, but for others rat over-estimated human biliary clearance by in excess of one order of magnitude. Based on a limited number of six drugs, multiple species allometry using unbound biliary clearance data gave good predictions, but it should be reflected on that inter-species allometry may to an extent afford better clinical predictions because of the smoothing out of data

DMD #49312

from species where there is a large discrepancy with the human data. Indeed, in a drug discovery setting, the most likely scenario is that a poor prediction of rat clearance from *in vitro* hepatic metabolic data would precipitate a renal and biliary excretion study if the compound is of sufficient interest as a potential human therapeutic agent. From such information accurate decisions must be made about the suitability of the compound to progress further and therefore, understanding rat to human differences in biliary clearance is vital.

To investigate this further we compiled an even more extensive rat and human biliary clearance data set than that of Morris *et al.*, for twenty two drugs of all charge types and several different therapeutic classes. For nine of the drugs it was also possible to find data for dog biliary clearance. An extensive literature search was performed to define the hepatic uptake and bile canalicular efflux drug transporters involved, with the aim of elucidating further the reason for inter-species differences and with the specific intention of helping DMPK scientists make effective decisions with early pre-clinical data.

DMD #49312

Materials and Methods

No new data was generated for this work - all data used was obtained from the scientific literature and the references used for this are detailed in Tables 1 and 2.

For rat and dog data, the methods in the publications all refer to biliary clearance estimated in the same way, as follows: Surgically prepared (bile duct cannulated) animals were used and the amount of parent drug eliminated into bile was quantified. Biliary clearance was then calculated from the product of the total systemic clearance and the fraction of dose accounted for in bile as parent drug (Table 3).

For the clinical studies, the literature references detailed the following methods for collecting the bile (see Table 4): In the majority of studies, patients had a temporary bile shunt (T-tube) inserted. The T-tube diverts part of the bile flowing from the liver to a port for external collection. Other studies used duodenal aspiration or drainage, in which biliary secretions were withdrawn from the duodenum. Parent drug was quantified in the bile samples, according to the methods detailed in the individual references and human biliary clearance was then calculated in one of three ways:

1. From the amount of parent drug in the bile divided by the area under the plasma concentration-time curve (Amount in bile/AUC, Table 4)
2. From the ratio of the rate of biliary excretion and the plasma concentration, either steady state or mid-point of the bile collection period (bil. excr. rate / $C_{p,ss}$ or bil. excr. rate / $C_{p,mid}$, Table 4)
3. From the product of the total systemic clearance (CL) and the fraction of dose accounted for in bile as parent drug (CL x %bile, Table 4) or in the same way

DMD #49312

but corrected for bioavailability (F) when the dose was administered orally (CL/F* %bile, Table 4).

In the source references for the human bile data (Table 1), the biliary clearance was not always calculated (in some of the publications, only the amount of parent drug excreted in to the bile was recorded). In these instances, we calculated the human biliary clearance by method 3 (above) using clearance and bioavailability values obtained from literature (Goodman and Gilman, 1990; Obach et al., 2008).

For the purposes of this present analysis (to assess the cross species differences in biliary clearance normalized for body weight and plasma protein binding and to determine if definition of the drug transporters involved help in elucidating the differences), the following steps were taken to supply the information in Table 1:

1. The biliary clearance was expressed in mL/min/kg terms, assuming rat, dog and human body weights of 0.3, 15 and 70 kg respectively. The body weight normalized biliary clearance (mL/min/kg) was divided by the fraction of each drug unbound in plasma (fup) to obtain the unbound biliary clearance. The following plasma protein binding data (rat, dog, human) were obtained from the scientific literature (where dog fup data was not required for the analysis, a dash (-) is given): Doxorubicin (0.34, 0.34, 0.28), digoxin (0.70, 0.49, 0.7), erythromycin (0.78, 0.53, 0.16), cefazolin (0.12, 0.74, 0.18), cefamandole (0.17, -, 0.25), cephalixin (0.76, -,0.86), cefotetan (0.70, 0.61, 0.15), cefixime (0.14, -,0.31), ceftriaxone (0.22, 0.86, 0.075), cefpiramide (0.54, 0.7, 0.04), cefoperazone (0.74, -, 0.07), valsartan (0.03, -, 0.04), moxalactam (0.51, -, 0.39), methotroxate (0.77, 0.63, 0.37), pravastatin (0.35, -, 0.5), diclofenac

DMD #49312

(0.009, -, 0.005), ranitidine (0.9, -, 0.95), vincristine (0.39, -, 0.4), methadone (0.36, -, 0.21), fexofenadine (0.19, -, 0.35), ciprofloxacin (0.57, -, 0.7) and napsagatran (0.33, 0.52, 0.55).

2. A literature search was performed to identify the human hepatic uptake and canalicular efflux drug transporters implicated in the *in vivo* biliary clearance. The references are given in Table 2.

DMD #49312

Results

In the analysis presented here, rat, dog and human differences in biliary clearance were explored by assembling, from the scientific literature, the most extensive database available to date. Additional definition of the uptake and efflux drug transporters involved was incorporated, with the intention of providing greater insight into the likely extent of cross-species differences. From this it is hoped that more enlightened early decision making may be possible in a Drug Discovery setting.

As with previous literature analyses, to overcome species differences in plasma protein binding, unbound biliary clearances were compared. In the analysis presented here, biliary clearance values were also normalized for body weight and presented in units of mL/min/kg body weight to allow a simpler cross-species comparison. Comparing rat, dog and human hepatic blood flow values of 72, 55 and 20 mL/min/kg (Barter et al., 2007; Taylor et al., 2007; McEntee et al 1996), one may expect a 3.6-fold difference between rat and human and a 2.8-fold difference between dog and human hepatic clearance in the absence of any mechanistic differences at the level of drug transport and metabolism. In this context, the most striking thing about the data set (Table 1, figure 1) is that for nineteen of the drugs (86%), rat unbound biliary clearance values exceed those for man by factors ranging from 9 to over 2500-fold.

DMD #49312

Discussion

Of the nineteen drugs with a rat/human unbound biliary clearance ratio of approximately one order of magnitude or greater, it was possible to find literature references for hepatic uptake transporter involvement for nine (Table 2, figure 2a). However, since four of those drugs with un-defined hepatic uptake mechanisms (cefixime, cefamandole, cefotetan and cefpiramide) have similar properties to ceftriaxone, cefazolin, cephalixin and cefoperazone (structurally similar acidic drugs of the same antibiotic class with low $\log D_{7.4}$ values and similar biliary efflux transporter substrate recognition) it is perhaps not unreasonable to speculate that the uptake transporters may also be similar – in other words the organic anion transporting polypeptides may be involved. It should however be acknowledged that the most lipophilic of these, ceftriaxone, is a substrate for OATP1B3 (Yamaguchi et al., 2011) but is not apparently a substrate for rat *oatp1a4* (Nakakariya et al., 2008a). Biliary efflux transporter involvement could be defined for the majority of the twenty two drugs but no obvious relationship between the transporter definition and the rat/human discrepancy in unbound biliary clearance was apparent (Table 2, figure 2b).

Methadone, cefazolin and moxalactam (0.001, 0.001 and 0.003 mL/min/kg) had by far the lowest measured total human biliary clearance values and the rat/human unbound biliary clearance differences were calculated to range from approximately 500 to 2500. With the human biliary clearance values being so low and patient numbers being limited (one, five and six for the three drugs respectively), the absolute values should be treated with caution. Methadone is of particular concern since it has the highest estimated rat/human discrepancy and yet is a basic drug of

DMD #49312

moderate to low lipophilicity. It is therefore unlikely to be an OATP substrate and the human biliary clearance value we found in the literature (Kreek et al., 1980) may not be a true representation in a wider patient group.

Interestingly, for the only three drugs where unbound rat, human and dog biliary clearance values were found to be approximately equal (in mL/min/kg), namely erythromycin, doxorubicin and digoxin (Table 1, figure 2a), active uptake into the liver has been reported to be at best very slow or only partially responsible for the permeability of the sinusoidal membrane or indeed non-existent (Yabe et al., 2011; Taub et al., 2011; Bi et al., 2006; Sun et al., 2004; Hilmer et al., 2004). Therefore, whilst there are dramatic species differences in the expression and activity of canalicular transporters that maybe up to ten-fold for rat/human Mrp2/MRP2 (Ishizuka et al., 1999; Li et al., 2009), the fact that erythromycin, doxorubicin and digoxin are substrates for P-gp or MRP2, along with many of the other drugs for which rat biliary clearance is considerably greater than for man, suggests that the key determinant in the biliary clearance species difference may indeed be the uptake step from the blood into the liver. It is not a new suggestion that sinusoidal active uptake from the blood into the liver may often be the rate limiting step for drugs cleared by biliary excretion (Yamazaki et al., 1996) and a similar inference comes from a recent study of 123 compounds showing significant excretion into rat bile and having considerable overlap in the physicochemical space occupied by human OATP and rat oatp substrates (Varma et al., 2012). Given this, the observation that rat biliary clearance exceeds that of human once normalized for body weight is perhaps not surprising, since functionally rat hepatic uptake transporters are more efficient than their human counterparts whilst dog hepatic uptake rates appear

DMD #49312

similar or lower than for human when one compares hepatocyte uptake data for the same actively transported drugs (Gardiner and Paine, 2011; Wilby et al., 2011; Grime et al., 2008; Soars et al., 2007).

Based on these observations we postulate that when drugs do not require active hepatic uptake to access the liver, there may be fairly insignificant differences in rat, dog and human biliary clearance once normalized for body weight and plasma protein binding differences. Conversely, when the organic anion-transporting polypeptide drug transporters are involved, one may expect at least a ten-fold discrepancy in rat to human biliary clearance (figure 2a). Additionally, based on very limited dog to human findings, one may expect very little dog/human discrepancy in biliary clearance regardless of the processes involved. Ultimately this may infer that *in vitro* hepatocyte active uptake intrinsic clearance data may be used to predict total hepatic clearance without the need to define the final fate of the drug, be it metabolized or excreted in the bile. This certainly appears to be the case for pravastatin (Soars et al., 2007). Although this is only an emerging perspective based on an analysis of the available literature, we believe it to be a useful indicator to Drug Discovery DMPK scientists handling rat biliary clearance data in a pre-clinical setting when rapid but educated decisions are required. Towards drug candidate selection at the pre-clinical / clinical development interface, biliary clearance data from multiple species will of course help in minimizing the risk of a poor human prediction (Morris et al., 2012) and a pharmacokinetic modeling/simulation approach, taking into account all the relevant processes and *in vitro* data to facilitate more precise predictions of human biliary clearance should be a strong consideration (Kusuhara and Sugiyama 2010; Swift et al., 2010). Future

DMD #49312

work to further understanding should certainly involve a detailed package of *in vitro* work, with the drugs discussed here, to define the active uptake intrinsic clearance values in rat, dog and human hepatocytes and to more fully define the transporter information.

DMD #49312

Acknowledgments

Thanks to Prabha Peramuhendige for her help in compiling the database and thanks to Constanze Hilgendorf for careful review of, and suggestions on, the manuscript.

Authorship Contributions

Participated in research design: Ken Grime and Stuart Paine

Performed data analysis: Ken Grime and Stuart Paine

Wrote or contributed to the writing of the manuscript: Ken Grime

DMD #49312

References

Abe K, Bridges AS and Brouwer KL (2009) Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors *Drug Metab Dispos.* **37**:447-452.

Arvidsson A, Alván G, Angelin B, Borgå O and Nord CE (1982) Ceftriaxone: renal and biliary excretion and effect on the colon microflora. *J Antimicrob Chemother* **10**:207-15.

Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, Houston JB, Lake BG, Lipscomb JC, Pelkonen OR, et al. (2007). Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: Reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. *Current Drug Metabolism* **8**:33–45.

Bi YA, Kazolias D and Duignan DB. (2006) Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport. *Drug Metab Dispos* **34**:1658-65

Bourdet DL, Pritchard JB and Thakker DR (2005) Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). *J Pharmacol Exp Ther* **315**: 1288-1297.

DMD #49312

Brogard JM, Audhuy B, Pinget M and Dorner M (1984) Evaluation of the biliary passage of beta-lactam antibiotics. *Ann Med Interne*. **135**:512-518.

Brogard JM, Jehl F, Adloff M, Blickle JF and Monteil H (1988) High hepatic excretion in humans of cefpiramide, a new cephalosporin. *Antimicrob Agents Chemother*. **32**: 1360-1364.

Brown CDA, Sayer R, Windass AS, Haslam IS, De Broe ME, D'Haese PC, Verhulst, A (2008) Characterisation of human tubular cell monolayers as a model of proximal tubular xenobiotic handling. *Toxicol. App. Pharmacol*. **233**: 428–438.

Brookman LJ, Rolan PE, Benjamin IS, Palmer KR, Wyld PJ, Lloyd P, Flesch G, Waldmeier F, Sioufi A and Mullins F (1997) Pharmacokinetics of valsartan in patients with liver disease. *Clin Pharmacol Ther* **62**: 272-278.

Choi MK, Kim H, Han YH, Song IS and Shim CK (2009) Involvement of Mrp2/MRP2 in the species different excretion route of benzylpenicillin between rat and human. *Xenobiotica* **39**: 171-181.

Cvetkovic M, Leake B, Fromm MF, Wilkinson GR and Kim RB (1999) OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. *Drug Metab Dispos* **27**: 866-871.

DMD #49312

Fujiwara K, Shin M and Miyazaki T (2011) A probable relationship between characteristic accumulation of doxorubicin and P-glycoprotein transporter in rat liver. *J Mol Histol* **42**: 409-415.

Gardiner P and Paine SW (2011) The impact of hepatic uptake on the pharmacokinetics of organic anions. *Drug Metab Dispos.* **39**:1930-1938.

Goodman and Gilman (1990) *The Pharmacological Basis of Therapeutics*, 10th ed. McGraw Hill Publishers, New York.

Grime K and Riley RJ (2006) The Impact of In Vitro Binding on In Vitro - In Vivo Extrapolations, Projections of Metabolic Clearance and Clinical Drug-Drug Interactions. *Current Drug Metabolism* **7**: 251-264.

Grime K, Webborn PJ, Riley RJ (2008) Functional consequences of active hepatic uptake on cytochrome P450 inhibition in rat and human hepatocytes. *Drug Metab Dispos.* **36**:1670-1678.

Gui C, Obaidat A, Chaguturu R and Hagenbuch B (2010) Development of a cell-based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3. *Curr Chem Genomics* **1**: 414-8.

Hariharan S, Gunda S, Mishra GP, Pal D and Mitra AK (2009) Enhanced Corneal Absorption of Erythromycin by Modulating P-Glycoprotein and MRP Mediated Efflux with Corticosteroids. *Pharmaceutical Research* **26**: 1270-1282.

DMD #49312

Hatanaka T, Honda S and Sasaki S (1998) Pharmacokinetic and pharmacodynamic evaluation for tissue-selective inhibition of cholesterol synthesis by pravastatin. *J Pharmacokinet Biopharm* **26**: 329-347.

Hedman A, Angelin B, Arvidsson A, Dahlqvist R (1991) No effect of probenecid on the renal and biliary clearances of digoxin in man. *Br J Clin Pharmacol*. **32**:63-67.

Hidemura K, Zhao YL, Ito K, Nakao A, Tatsumi Y, Kanazawa H, Takagi K, Ohta M and Hasegawa T (2003) Shiga-like toxin II impairs hepatobiliary transport of doxorubicin in rats by down-regulation of hepatic P glycoprotein and multidrug resistance-associated protein Mrp2. *Antimicrob Agents Chemother* **47**: 1636-1642.

Hilmer SN, Cogger VC, Muller M and Le Couteur DG (2004) The hepatic pharmacokinetics of doxorubicin and liposomal doxorubicin. *Drug Metab Dispos* **32**: 794-799.

Huang SM, Tsai TR, Yeh PH and Tsai TH (2005) Measurement of unbound ranitidine in blood and bile of anesthetized rats using microdialysis coupled to liquid chromatography and its pharmacokinetic application. *J Chromatogr A* **1073**: 297-302.

Iguchi H, Tone H, Kiyosaki T, Ishikura T, Takeuchi T and Umezawa H (1986) Pharmacokinetics and disposition of (2''R)-4'-O-tetrahydropyranyladriamycin in dogs. *Jpn J Antibiot* **39**: 638-652.

DMD #49312

Ishizuka H, Konno K, Shiina T, Naganuma H, Nishimura K, Ito, K, Suzuki H and Sugiyama Y (1999) Species differences in the transport activity for organic anions across the bile canalicular membrane. *J. Pharmacol. Exp. Ther* 290: 1324-1330.

Jackson DV Jr, Castle MC and Bender RA (1978) Biliary excretion of vincristine. *Clin Pharmacol Ther.* **24**: 101-107.

Jaisue S, Gerber JP and Davey AK (2010) Pharmacokinetics of fexofenadine following LPS administration to rats. *Xenobiotica* **40**: 743–750.

Kato Y, Takahara S, Kato S, Kubo Y, Sai Y, Tamai I, Yabuuchi H and Tsuji A (2008) Involvement of multidrug resistance-associated protein 2 (Abcc2) in molecular weight-dependent biliary excretion of beta-lactam antibiotics. *Drug Metab Dispos* **36**: 1088-96.

Kemmerich B, Lode H, Borner K, Belmega D, Jendroschek T, Koeppe P and Goertz G (1983) Biliary excretion and pharmacokinetics of cefoperazone in humans.

Klotz U and Walker S (1990) Biliary excretion of H₂-receptor antagonists. *Eur J Clin Pharmacol* **1**: 91-92.

Koike K, Kawabe T, Tanaka T, Toh S, Uchiumi T, Wada M, Akiyama S, Ono M and Kuwano M (1997) A canalicular multispecific organic anion transporter (cMOAT)

DMD #49312

antisense cDNA enhances drug sensitivity in human hepatic cancer cells. *Cancer Res* **57**: 5475-5479.

Kreek MJ, Kalisman M, Irwin M, Jaffery NF and Scheflan M (1980) Biliary secretion of methadone and methadone metabolites in man. *Res Commun Chem Pathol Pharmacol* **29**: 67-78.

Krishna R, McIntosh N, Riggs KW, Mayer LD (1999) Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of valsopodar (PSC 833) under conditions that significantly inhibit nonencapsulated drug excretion. *Clin Cancer Res.* **5**:2939-2947.

Kusuhara H and Sugiyama Y (2010) Pharmacokinetic modeling of the hepatobiliary transport mediated by cooperation of uptake and efflux transporters. *Drug Metab Revs* **42**: 539–550.

Lavé T, Chapman K, Goldsmith P, Rowland M (2009) Human clearance prediction: shifting the paradigm. *Exp. Opin. Drug Metab. Toxicol.* **9**: 1039-1048.

Lam JL, Okochi H, Huang Y, Benet LZ (2006) In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter-enzyme interplay. *Drug Metab Dispos.* **34**:1336-1344.

DMD #49312

LeCluyse EL, Audus KL, Hochman JH (1994) Formation of extensive canalicular networks by rat hepatocytes cultured in collagen-sandwich configuration. *Am. J. Physiol.* **266**: C1764-1774.

Li N, Zhang Y, Hua F, Lai Y (2009) Absolute Difference of Hepatobiliary Transporter Multidrug Resistance-Associated Protein (MRP2/Mrp2) in Liver Tissues and Isolated Hepatocytes from Rat, Dog, Monkey, and Human. *Drug Metab Dispos.* **37**: 66-73.

Mahmood I (2005) Interspecies scaling of biliary excreted drugs: a comparison of several methods. *J. Pharm. Sci.* **94**: 883-892.

Mahmood I and Sahajwalla C (2002) Interspecies scaling of biliary excreted drugs. *J Pharm Sci.*, **91**:1908-1014.

Matsui H, Komiya M, Ikeda C and Tachibana A (1984) Comparative pharmacokinetics of YM-13115, ceftriaxone, and ceftazidime in rats, dogs, and rhesus monkeys. *Antimicrob Agents Chemother* **26**: 204-207.

Matsui H, Yano K and Okuda T (1982) Pharmacokinetics of the cephalosporin SM-1652 in mice, rats, rabbits, dogs, and rhesus monkeys. *Antimicrob Agents Chemother* **22**: 213-217.

Matsushima S, Maeda K, Hayashi H, Debori Y, Schinkel AH, Schuetz JD, Kusuhara H and Sugiyama Y (2008) Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. *Mol Pharmacol* **73**: 1474-1483.

DMD #49312

McEntee K, Clercx C, Pypendop B, Peeters D, Balligand M, D'Orio V, Henroteaux M (1996) Cardiac performance in conscious healthy dogs during dobutamine infusion. *Res Vet Sci* **61**: 234-239.

McGinnity DF, Collington J, Austin RP and Riley RJ (2007) Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs. *Curr Drug Metab* **8**: 463-479.

Miyazawa Y, Sato T, Kobayashi K, Akahori F, Suzuki T and Miyashita H (1990) Influence of induced cholestasis on pharmacokinetics of digoxin and digitoxin in dogs. *Am J Vet Res* **51**: 605-610.

Mizojiri K, Norikura R, Takashima A, Tanaka H, Yoshimori T, Inazawa K, Yukawa T, Okabe H and Sugeno K (1987) Disposition of moxalactam and N-methyltetrazoethiol in rats and monkeys. *Antimicrob Agents Chemother* **31**: 1169-1176.

Morris M, Yang Y, Gandhi YA, Bhansalia SG and Benincosa LJ (2012) Interspecies scaling: prediction of human biliary clearance and comparison with QSPKR. *Biopharm. Drug Dispos.* **33**: 1–14.

Muraoka I, Hasegawa T, Nadai M, Wang L, Haghgoo S, Tagaya O and Nabeshima T (1995) Biliary and renal excretions of cefpiramide in Eisai hyperbilirubinemic rats. *Antimicrob Agents Chemother* **39**: 70-74.

DMD #49312

Nakakariya M, Ono M, Amano N, Moriwaki T, Maeda K, Sugiyama Y (2012)

In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes. *Drug Metab Dispos.* **40**: 602-609.

Nakakariya M, Shimada T, Irokawa M, Maeda T and Tamai I (2008a) Identification and species similarity of OATP transporters responsible for hepatic uptake of beta-lactam antibiotics. *Drug Metab Pharmacokinet* **23**: 347–355

Nakakariya M, Shimada T, Irokawa M, Koibuchi H, Iwanaga T, Yabuuchi H, Maeda T and Tamai I (2008b) Predominant contribution of rat organic anion transporting polypeptide-2 (Oatp2) to hepatic uptake of beta-lactam antibiotics. *Pharm Res.* **25**: 578-85.

Obach RS (2011) Predicting clearance in humans from in vitro data. *Curr. Top. Med. Chem.* **11**; 334-339.

Obach RS, Lombardo F and Waters NJ (2008) Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 670 Drug Compounds. *Drug Metab Dispos* **36**: 1385–1405.

Paine SW, Menochet K, Denton R, McGinnity, DF, Riley RJ. (2011) Prediction of Human Renal Clearance from Preclinical Species for a Diverse Set of Drugs That Exhibit Both Active Secretion and Net Reabsorption. *Drug Metab. Dispos.* **39**: 1008–1013.

DMD #49312

Peris-Ribera JE, Torres-Molina F, Garcia-Carbonell MC, Aristorena JC and Pla-Delfina JM (1991) Pharmacokinetics and bioavailability of diclofenac in the rat. *J Pharmacinet Biopharm* **19**: 647-665.

Påhlman I, Edholm M, Kankaanranta S, Odell M-L (1998) Pharmacokinetics of Susalimod, a highly biliary excreted sulphasalazine analogue, in various species. Non predictable human clearance by allometric scaling. *Pharm. Pharmacol. Comm.* **4**: 493-498.

Ratzan KR, Baker HB, Lauredo I (1978) Excretion of cefamandole, cefazolin, and cephalothin into T-tube bile. *Antimicrob Agents Chemother.* **13**:985-987.

Rodriguez M, Ortega I, Soengas I, Suarez E, Lukas JC and Calvo R (2004) Effect of P-glycoprotein inhibition on methadone analgesia and brain distribution in the rat. *J Pharm Pharmacol* **56**: 367-374.

Saikawa I, Takai A, Nakashima Y, Ikegami T, Hayakawa H, Takagi T and Yamauchi H (1980) Studies on the absorption distribution and excretion of ¹⁴C-labelled sodium 7-[D(-)-alpha-(4-ethyl-2,3-dioxo-1-piperazine-carboxamido)-alpha-(4-hydroxyphenyl) acetamido]-3-[(1-methyl-1H-tetrazol-5-yl) thiomethyl]-3-cephem-4-carboxylate (¹⁴C-cefoperazone) in rats and mice. *Jpn J. Antibiot.* **33**: 1084-1096.

Sasaki M, Suzuki H, Aoki J, Ito K, Meier PJ and Sugiyama Y (2004) Prediction of in Vivo Biliary Clearance from the in Vitro Transcellular Transport of Organic Anions across a Double-Transfected Madin-Darby Canine Kidney II Monolayer Expressing

DMD #49312

Both Rat Organic Anion Transporting Polypeptide 4 and Multidrug Resistance Associated Protein 2. *Mol Pharmacol* **66**: 450–459.

Sawada Y, Hanano M, Sugiyama Y, Iga T (1984) Prediction of the disposition of β -lactam antibiotics in humans from pharmacokinetic parameters in animals. *J. Pharmacokinetics and Biopharm.* **12**: 241-260.

Scatina JA, Hicks DR, Kraml M, Cayen MN (1989) Disposition of a new tetrahydrocarbazole analgesic drug in laboratory animals and man. *Xenobiotica.* **19**: 991-1002.

Shitara Y, Horie T and Sugiyama Y (2006) Transporters as a determinant of drug clearance and tissue distribution. *Eur. J. Pharm. Sci.* **27**: 425-446.

Soars MG, Grime K, Sproston JL, Webborn PJ and Riley RJ (2007) Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo. *Drug Metab Dispos.* **35**:859-865.

Sohlenius-Sternbeck A-K, Jones C, Ferguson D, Middleton BJ, Projean D, Floby E, Bylund J and Afzelius L (2012) Practical use of the regression offset approach for the prediction of in vivo intrinsic clearance from hepatocytes. *Xenobiotica* **42**: 841-853.

Song S, Suzuki H, Kawai R and Sugiyama Y (1999) Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. *Drug Metab Dispos* **6**: 689-694.

DMD #49312

Stierlin H and Faigle JW (1979) Biotransformation of diclofenac sodium (Voltaren) in animals and in man. II. Quantitative determination of the unchanged drug and principal phenolic metabolites, in urine and bile. *Xenobiotica* **9**: 611-621.

Sun H, Huang Y, Frassetto L and Benet LZ (2004) Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. *Drug Metab Dispos* **32**: 1239–1246.

Sutfin TA, Gabrielsson M and Regårdh CG (1987) Effects of biliary excretion on the disposition of felodipine and metabolites in the rat. *Xenobiotica* **17**: 1203-1214.

Swift B, Yue W and Brouwer KLR (2010) Evaluation of 99mTechnetium-Mebrofenin and 99mTechnetium-Sestamibi as Specific Probes for Hepatic Transport Protein Function in Rat and Human Hepatocytes. *Pharm Res.* **27**:1987–1998.

Takimura Y and Lopez-Belio M (1955) Excretion of erythromycin through the biliary tract. *Antibiotic Med Clin Ther.* **1**:561-566.

Tahara H, Kusuhara H, Fuse E and Sugiyama Y (2005) P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion. *Drug Metab Dispos.* **33**: 63-968.

Tanimura H, Tominaga S, Rai F and Matsumoto H. (1986) Transfer of ciprofloxacin to bile and determination of biliary metabolites in humans. *Arzneimittelforschung.* **36**: 417-1420.

DMD #49312

Taylor GL, Patel B and Sullivan AT (2007). Evaluation of blood flow parameters in addition to blood pressure and electrocardiogram in the conscious telemetered beagle dog. *J Pharmacol Toxicol Methods* **56**: 212-217.

Taub ME, Mease K, Sane RS, Watson CA, Chen L, Ellens H, Hirakawa B, Reyner EL, Jani M and Lee CA (2011) Digoxin is not a substrate for organic anion-transporting polypeptide transporters OATP1A2, OATP1B1, OATP1B3, and OATP2B1 but is a substrate for a sodium-dependent transporter expressed in HEK293 cells. *Drug Metab Dispos* **39**: 2093-2102.

Tsuji A, Yoshikawa T, Nishide K, Minami H, Kimura M, Nakashima E, Terasaki T, Miyamoto E, Nightingale CH and Yamana T (1983) Physiologically based pharmacokinetic model for beta-lactam antibiotics I: Tissue distribution and elimination in rats. *J Pharm Sci.* **72**:1239-1252.

Uchida K, Konishi M, Akiyoshi T, Igimi H and Asakawa S (1985) Biliary excretion of latamoxef and N-methyltetrazoethiol in humans and rats. *J Pharmacobiodyn* **8**: 981-988.

van Zanden JJ, de Mul A, Wortelboer HM, Usta M, van Bladeren PJ, Rietjens IM and Cnubben NH (2005) Reversal of in vitro cellular MRP1 and MRP2 mediated vincristine resistance by the flavonoid myricetin. *Biochem Pharmacol* **69**: 1657-1665.

DMD #49312

Varma MV, Chang G, Lai Y, Feng B, El-Kattan AF, Litchfield J, Goosen TC (2012) Physicochemical property space of hepatobiliary transport and computational models for predicting rat biliary excretion. *Drug Metab Dispos.* **40**: 1527-1537.

Wang Z, Hamman MA, Huang S-M, Lesko LJ and Hall SD (2002) Effect of St John's wort on the pharmacokinetics of fexofenadine. *Clinical Pharmacology and Therapeutics* **71**: 414-420.

Watanabe T, Kusuhara H, Maeda K, Shitara Y and Sugiyama Y (2009) Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans. *The Journal of Pharmacology and Therapeutics* **328**: 652-662.

Watanabe T, Suzuki H, Sawada Y, Naito M, Tsuruo T, Inaba M, Hanano M and Sugiyama Y (1995) Induction of hepatic P-glycoprotein enhances biliary excretion of vincristine in rats. *J Hepatol* **23**: 440-448.

Westphal JF, Jehl F, Schloegel M, Monteil H and Brogard JM (1993) Biliary excretion of cefixime: assessment in patients provided with T-tube drainage. *Antimicrob Agents Chemother* **37**: 1488-1491.

Wilby AJ, Maeda K, Courtney PF, Debori Y, Webborn PJ, Kitamura Y, Kusuhara H, Riley RJ, Sugiyama Y (2011) Hepatic Uptake in the Dog: Comparison of Uptake in Hepatocytes and Human Embryonic Kidney Cells Expressing Dog Organic Anion-Transporting Polypeptide 1B4. *Drug Met Dispos* **39**: 2361–2369.

DMD #49312

Wilkinson PM, Israel M, Pegg WJ, Frei E (1979) Comparative metabolism and excretion of adriamycin in man, monkey, and rat. *Cancer Chemother Pharmacol.* **2**:121-125.

Wright WE and Line VD (1980) Biliary excretion of cephalosporins in rats: influence of molecular weight. *Antimicrob Agents Chemother.* **17**:842-846.

Wyman JB, Bartholomew LG, Karlson AG, Wakim KG, Cain JC (1968) Pancreatic, hepatic, and renal excretion of antibiotics in dogs. Observations on erythromycin, lincomycin, kanamycin, and colistimethate excretion. *Archives of Surgery* **97**: 46-50.

Yabe Y, Galetin A, Houston JB (2011) Kinetic characterization of rat hepatic uptake of 16 actively transported drugs. *Drug Metab Dispos.* **39**:1808-1814.

Yamaguchi H, Takeuchi T, Okada M, Kobayashi M, Unno M, Abe T, Goto J, Hishinuma T, Shimada M and Mano N (2011) Screening of antibiotics that interact with organic anion-transporting polypeptides 1B1 and 1B3 using fluorescent probes. *Biol Pharm Bull* **34**: 389-395.

Yamaguchi H, Yano I, Saito H and Inui K (2004) Effect of cisplatin-induced acute renal failure on bioavailability and intestinal secretion of quinolone antibacterial drugs in rats. *Pharm Res* **21**: 330-338.

DMD #49312

Yamashiro W, Maeda K, Hirouchi M, Adachi Y, Hu Z and Sugiyama Y (2006) Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. *Drug Met Dispos* **34**: 1247-1254.

Yamazaki M, Tokui T, Ishigami M and Sugiyama Y (2006) Tissue-selective uptake of pravastatin in rats: contribution of a specific carrier-mediated uptake system. *Biopharm Drug Dispos*. **17**:775-789.

Yasui H, Yamaoka K and Nakagawa T (1994) Alternative continuous infusion method for analysis of enterohepatic circulation and biliary excretion of cefixime in the rat. *J Pharm Sci*. **83**: 819-823.

Yoshikawa N, Tsuji Y, Sato Y, Ikeda Y, Shinada Y, Kawanishi N, Tamaki A and Kasai Y (1979) Experimental study of the biliary excretion of antibiotic (cefotiam) in the presence of biliary tract obstruction. *Jpn J Antibiot* **32**: 1101-1016.

DMD #49312

Figure Legends

Figure 1: Relationship between human and animal (rat, closed circles and dog, open squares) unbound biliary clearance. The solid line is the line of unity and the dashed line is ten-fold from unity)

Figure 2: Relationship between human and rat unbound biliary clearance and the involvement of human hepatic drug transporters: A, hepatic uptake transporter definition with closed black circles representing drugs with no/slow active uptake, closed red circles representing substrates for OATP1B1/3, open red circles representing drugs (cefixime, cefamandole, cefotetan and cefpiramide) that are likely to be substrates for OATP1B1/3 (based on drug class, structural and physico-chemical similarity to cefixime, cefamandole, cefotetan and cefpiramide) but for which no literature evidence was found, the closed blue circle is ranitidine, an OCT-1 substrate and the open circles represent drugs for which literature evidence was not found to define the transporters involved; B, hepatic canalicular efflux transporter definition with green circles representing P-gp substrates, open triangles representing MRP2 substrates, green triangles representing MRP2 and P-gp substrates, blue circles representing BCRP substrates, blue triangles representing BCRP and MRP2 substrates and crosses representing drugs where no efflux transporter reference was found in the literature.

DMD #49312

TABLE 1: Human, rat and dog biliary clearance, presented in units of mL/min/kg as total (CL_{bile}) and unbound (CL_{bile,u}) after adjusted for plasma protein binding

	Human CL _{bile}	Human CL _{bile,u}	Rat CL _{bile}	Rat CL _{bile,u}	Dog CL _{bile}	Dog CL _{bile,u}
Doxorubicin	2.035 ^a	7.268	3.68 ^b	10.82	1.720 ^c	5.059
Digoxin	1.595 ^d	2.279	3.03 ^e	4.329	1.313 ^f	2.680
Erythromycin	1.147 ^g	7.169	17.4 ^h	22.38	2.376 ⁱ	4.483
Cefazolin	0.001 ^j	0.007	1.40 ^k	11.24	0.066 ^l	0.089
Cefamandole	0.012 ^m	0.048	5.00 ⁿ	29.41		
Cephalexin	0.0134 ^o	0.016	1.07 ^o	1.408		
Cefotetan	0.048 ^o	0.320	6.14 ^o	8.771	0.696 ^o	1.141
Cefixime	0.140 ^p	0.452	1.00 ^q	7.143		
Ceftriaxone	0.070 ^r	0.933	0.82 ^s	12.73	2.5 ^s	2.907
Cefpiramide	0.040 ^t	1.000	5.22 ^u	9.667	0.979 ^v	1.399
Cefoperazone	0.149 ^w	2.129	16.3 ^x	22.03		
Valsartan	0.431 ^y	10.775	12.5 ^z	378.8		
Moxalactam	0.003 ^{aa}	0.008	2.19 ^{ab}	4.294		
Methotrexate	0.048 ^o	1.108	9.60 ^o	12.47	0.217 ^o	0.344
Pravastatin	3.105 ^{ac}	6.210	27.5 ^{ad}	78.57		
Diclofenac	0.042 ^{ae}	8.400	0.85 ^{af}	94.44		
Ranitidine	0.153 ^{ag}	0.161	1.40 ^o	1.556		
Vincristine	0.209 ^{ah}	0.523	33.1 ^{ai}	84.87		
Methadone	0.001 ^{aj}	0.006	5.22 ^{ak}	14.33		
Fexofenadine	1.400 ^{al}	4.000	8.00 ^{am}	42.11		
Ciprofloxacin	0.059 ^{an}	0.084	3.50 ^{ao}	6.140		
Napsagatran	4.357 ^o	7.922	34.7 ^o	105.2	32.75 ^o	62.98

a. Wilkinson et.al. 1979; b. Krishna et al., 1999; c. Iguchi et al., 1986; d. Hedman A. et.al. 1991; e. Song et al., 1999; f. Miyazawa et al., 1990 ; g. Takimura et al., 1955; h. Lam et al., 2006; i. Wyman et al., 1968; j. Brogard et.al. 1984; k. Tsuji et al., 1983; l. Yoshikawa, 1979; m. Ratzan et al., 1978; n. Wright et al., 1980; o. Morris et al., 2011; p. Westphal et al., 1993; q. Yasui et al., 1994; r. Arvidsson et al., 1982; s. Matsui et al., 1984; t. Brogard et al., 1988; u. Muraoka et al., 1995; v. Matsui et al., 1982; w. Kemmerich et al., 1983; x. Saikawa et al., 1980; y. Brookman et al., 1997; z. Yamashiro et al., 2006; aa. Uchida et al., 1985; ab. Mizojiri et al., 1987; ac. Sasaki et al., 2004; ad. Hatanaka et al., 1998; ae. Stierlin H et al., 1979; af. Peris-Ribera et al., 1991; ag. Klotz et ai., 1990; ah. Jackson et al., 1978; ai. Song et al., 1999; aj. Kreek et al., 1980; ak. Suffin et al., 1987; al. ALLEGRA Product Monograph, Sanofi-

DMD #49312

Aventis Canada Inc., <http://products.sanofi.ca/en/allegro.pdf> and Wang et al., 2002;
am. Tahara et al., 2005 and Jaisue et al., 2010; an. Tanimura et.al. 1986; ao.
Yamaguchi et al., 2004.

DMD #49312

TABLE 2: Rat/human and dog/human unbound biliary clearance ratios and assignment of hepatic drug transporter involvement

	Rat / human CL _{bile,u}	Dog / human CL _{bile,u}	hepatic uptake transporter	biliary efflux transporter	Chemo -type
Doxorubicin	1	1	-	MRP2; P-gp ^{a,b,c}	b
Digoxin	2	1	-	P-gp ^d	n
Erythromycin	3	1	-	MRP2; P-gp ^e	b
Cefazolin	1685	13	OATP1B1, 1B3 ^f	BCRP ^g	a
Cefamandole	613		*	MRP2, BCRP ^h	a
Cephalexin	90		OATP1B1, 1B3 ^f	*	a
Cefotetan	27	4	*	BCRP ^g	a
Cefixime	16		*	*	a
Ceftriaxone	14	3	OATP1B3 ^{f,h}	MRP2 ^g	a
Cefpiramide	10	1	*	MRP2, BCRP ^g	a
Cefoperazone	10		OATP1B1, 1B3 ^{h,i}	MRP2, BCRP ^g	a
Valsartan	35		OATP1B1, 1B3 ^j	MRP2 ^j	a
Moxalactam	507		*	*	a
Methotrexate	11	3	OATP1B1 ^k	MRP2 ^l	a
Pravastatin	13		OATP1B1 ^m	MRP2 ⁿ	a
Diclofenac	11		*	*	a
Ranitidine	10		OCT-1 ^o	P-gp ^p	b
Vincristine	162		*	MRP2; P-gp ^{q,r}	b
Methadone	2508		*	P-gp ^s	b
Fexofenadine	11		OATP1B1, 1B3 ^{t,u}	P-gp ^u	z
Ciprofloxacin	73		*	*	z
Napsagatran	13	8	*	*	z

- Literature indicates no or inefficient active hepatic uptake;

* Indicates that no literature reference was found;

a, b, n, z in the final column indicates acid, base, neutral and zwitterionic drug.

Literature references for the transporter definition: a. Fujiwara et al., 2011; b. Hidemura et al., 2003; c. Koike et al., 1997; d. Bi et al., 2006; e. Hariharan et al., 2009; f. Nakakariya et al., 2008a; g. Kato et al., 2008; h. Yamaguchi et al., 2011; i. Nakakariya et al., 2008b; j. Yamashiro et al., 2006; k. Gui et al., 2010; l. Choi et al., 2009; m. Kusuhara & Sugiyama 2010; n. Watanabe et al., 2009; o. Bourdet et al., 2005; p. Huang et al., 2005; q. van Zanden et al., 2005; r. Watanabe et al., 1995; s. Rodriguez et al, 2004; t. Matsushima et al., 2008; u. Cvetkovic et al., 1999.

DMD #49312

TABLE 3: Experimental rat and dog biliary excretion information used in the analysis

	Admin. Route (rat)	% dose excreted into bile (rat)	Admin. Route (dog)	% dose excreted into bile (dog)
Doxorubicin	i.v.	17	i.v.	10
Digoxin	i.v.	31	i.v.	7
Erythromycin	i.v.	30	i.v.	5
Cefazolin	i.v.	30	i.v.	2
Cefamandole	i.v.	33		
Cephalexin	i.v.	32		
Cefotetan	i.v.	48	i.v.	17
Cefixime	i.v.	41		
Ceftriaxone	i.v.	62	i.v.	63
Cefpiramide	i.v.	58	i.v.	19
Cefoperazone	i.v.	86		
Valsartan	i.v.	70		
Moxalactam	i.v.	25		
Methotrexate	i.v.	64		
Pravastatin	i.v.	40		
Diclofenac	i.v.	5		
Ranitidine	i.v.	5		
Vincristine	i.v.	43		
Methadone	i.v.	9		
Ciprofloxacin	i.v.	10		
Fexofenadine	i.v.	28		
Napsagatran	i.v.	61	i.v.	97

DMD #49312

TABLE 4: Experimental human biliary excretion information used in the analysis

	Calculation Method	% parent drug in bile	Admin. Route	Method	Collection Interval
Doxorubicin	CL x %bile	14	i.v.	T-tube	24 hr
Digoxin	bil. excr. rate /Cp, mid	41	i.v.	duodenal perf.	8 hr
Erythromycin	CL x %bile	13	i.v.	duodenal asp.	20 hr
Cefazolin	CL x %bile	0.1	i.v.	T-tube	
Cefamandole	CL x %bile	0.4	i.v.	T-tube	6 hr
Cephalexin			-		
Cefotetan	CL x %bile	11	i.v.	duodenal perf.	7 hr
Cefixime	Amount in bile/AUC	11	p.o	T-tube	24 hr
Ceftriaxone	bil. excr. rate /Cp,ss	30	i.v.	duodenal perf.	6-8 hr
Cefpiramide	Amount in bile/AUC	28	i.v.	T-tube	24 hr
Cefoperazone	CL x %bile	12	i.v.	T-tube	24 hr
Valsartan	CL x %bile	88	i.v.	T-tube	24 hr
Moxalactam	CL x %bile	0.5	i.v.	T-tube	8 hr
Methotrexate	CL x %bile	10	i.v.	T-tube	24 hr
Pravastatin	CL x %bile	23	i.v.	T-tube	24 hr
Diclofenac	CL x %bile	1	i.v.	T-tube	8 hr
Ranitidine	CL x %bile	1.5	i.v.	T-tube	24 hr
Vincristine	CL x %bile	10	i.v.	T-tube	72 hr
Methadone	CL/F x %bile	0.06	p.o	T-tube	24 hr
Ciprofloxacin	CL/F x %bile	0.5	p.o	T-tube	24 hr
Fexofenadine	CL/F x %bile	23	p.o	Fecal ext.	12 hr
Napsagatran	-	60	-		-

Ratio of biliary excretion rate and the steady state plasma concentration or mid-point plasma concentration during the bile collection period = (bil. excr. rate /Cp,ss or bil. excr. rate /Cp,mid);

Percentage of parent drug accounted for in bile = %bile; F = bioavailability and AUC = area under the plasma drug concentration-time profile; - indicates that the precise details of the procedure were not available in the literature;

Duodenal perf. = duodenal perfusion;

Duodenal asp. = duodenal aspiration;

Fecal ext. = Fecal extraction.

Figure 1




Figure 2

